Remove 2024 Remove Adverse Reactions Remove Dosage
article thumbnail

New Year, New Goals: 2024

The Thyroid Pharmacist

I am hoping to feel more settled in 2024. I am wrapping up some projects in early 2024 and I am carving out more time for myself and my own healing. In this article, I share a ton of natural solutions for everyday ailments, how to use each supplement, recommended dosages for each supplement, and precautions to be aware of.

article thumbnail

OPDP Says TV Ad is Out of Bounds with Fourth Untitled Letter of 2024

FDA Law Blog: Biosimilars

By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued its fourth Untitled Letter of 2024 – this one to AbbVie, Inc. The approved labeling for UBRELVY includes a warning and precaution regarding hypersensitivity reactions, with the most common adverse reactions being nausea and somnolence.

article thumbnail

USFDA approves injectable version of Bristol Myers Squibb’s Opdivo

Express Pharma

The most common adverse reactions (10 per cent) were fatigue, musculoskeletal pain, pruritus, rash, and cough. In general, CHECKMATE-67T showed a similar safety profile between OPDIVO QVANTIG and intravenous nivolumab.